Caroline Ingre

List of Publications by Year
in descending order

23 papers	891 citations	706676 14 h-index	685536 24 g-index
25 all docs	25 docs citations	25 times ranked	1564 citing authors

#	Article	IF	Citations
1	The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 45-53.	1.1	7
2	Dying from ALS in Sweden: clinical status, setting, and symptoms. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 237-245.	1.1	3
3	Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 58-65.	1.1	8
4	ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 209-219.	1.1	5
5	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
6	Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis. ELife, 2022, 11, .	2.8	18
7	Military service and related risk factors for amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2021, 143, 39-50.	1.0	19
8	Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 2021, 27, 640-646.	15.2	69
9	Mortality among family members of patients with amyotrophic lateral sclerosis â€“ a Swedish register-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-10.	1.1	1
10	Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa152.	1.5	21
11	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.1	20
12	No association between proton pump inhibitor use and ALS risk: a nationwide nested caseâ€“control study. Scientific Reports, 2020, 10, 13371.	1.6	7
13	Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology, 2020, 94, e1835-e1844.	1.5	42
14	Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis. Minerva Gastroenterologica E Dietologica, 2020, 66, 219-224.	2.2	4
15	Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20â€‰years of followâ€up. Annals of Neurology, 2019, 86, 913-926.	2.8	25
16	Complications and outcome of percutaneous endoscopic gastrostomy in a high-volume centre. Scandinavian Journal of Gastroenterology, 2019, 54, 513-518.	0.6	26
17	The Swedish motor neuron disease quality registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 528-537.	1.1	58
18	Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20â€year followâ€up of the Swedish AMORIS cohort. Annals of Neurology, 2017, 81, 718-728.	2.8	111

#	Article	IF	Citations
19	Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology, 2017, 89, 578-585.	1.5	36
20	Depression in amyotrophic lateral sclerosis. Neurology, 2016, 86, 2271-2277.	1.5	66
21	Predictors of health-related quality of life in people with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2016, 370, 269-273.	0.3	35
22	Amyotrophic lateral sclerosis among cross-country skiers in Sweden. European Journal of Epidemiology, 2016, 31, 247-253.	2.5	31
23	Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology, 2015, 7, 181.	1.5	272